Key Drivers
- Tax-boosted profit
- Improving liquidity
- Weak annual returns
AIAI Summary
LIVN has evolved into a quality-of-growth story: raised cardiopulmonary and epilepsy guidance and 70% gross margins create meaningful operating-leverage upside, but investors should require sustained normalized EBITDA and free-cash-flow conversion before paying a premium multiple, as reported earnings were largely tax-benefit driven.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Tax-boosted profit
- •Improving liquidity
- •Weak annual returns
LIVN's operating recovery and cash generation are encouraging, but tax-boosted earnings, weak annual profitability, high intangible exposure, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Weak momentum
- •Critical support
LIVN has weakened over the last month, with $78 support critical—hold for a rebound, but a break lower could extend losses toward resistance at $80.60–$80.70.
Declined from a $82.40 peak to $78.01, signaling elevated volatility
Sentiment & News
Key News Insights:
- •New Institutional Stake
- •Director Share Sale
- •Investor Conference
Squarepoint's new $1.4M stake signals institutional confidence, while a director's notable share sale warrants monitoring.
Institutional buying is supportive, but insider selling may temper near-term sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings